Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

Tonneijck, Lennart; Smits, Mark M; Muskiet, Marcel H A; Hoekstra, Trynke; Kramer, Mark H H; Danser, A H Jan; Ter Wee, Piet M; Diamant, Michaela; Joles, Jaap A; van Raalte, Daniel H

doi:https://doi.org/10.2337/dc19-er03

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

DSpace/Manakin Repository

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

Tonneijck, Lennart; Smits, Mark M; Muskiet, Marcel H A; Hoekstra, Trynke; Kramer, Mark H H; Danser, A H Jan; Ter Wee, Piet M; Diamant, Michaela; Joles, Jaap A; van Raalte, Daniel H

(2019) Diabetes Care, volume 42, issue 3, pp.

(Comment)

Download/Full Text

The full text of this publication is not available.

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Advanced and Specialised Nursing, Internal Medicine, Endocrinology, Diabetes and Metabolism, Published Erratum, Journal Article

DOI: https://doi.org/10.2337/dc19-er03

ISSN: 0149-5992

Publisher: American Diabetes Association Inc.

(Non peer reviewed)